

Fabtech[®]
Technologies Limited
Life Engineering[™]

Fabtech Technologies Limited

Investor Presentation

— Disclaimer

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Fabtech Technologies Limited, (The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantee of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.

These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks.

The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

Why Turnkey + In-House Manufacturing Matters

- In pharmaceutical, biopharma, and healthcare projects, choosing a turnkey partner with in-house **Process, Air & Water** manufacturing capabilities is no longer a preference, it's a strategic necessity.
- **Single Accountability, Zero Coordination Risk:** One partner owns design, engineering, manufacturing, installation, and validation eliminating delays and vendor conflicts.
- **Precision-Controlled Environments In-House:** Process Equipment & Containment Systems (Process), Cleanrooms (Air) & Purified Water & Distribution (Water) are engineered under one ecosystem ensuring seamless integration and regulatory compliance.
- **Speed to Market:** In-house manufacturing drastically reduces dependency on imports and fragmented suppliers accelerating delivery, qualification, and commercial launch.
- **Regulatory Confidence:** A unified turnkey approach ensures every system meets global cGMP, WHO, EU-GMP, USFDA, and ISO standards from the first blueprint to final validation.
- **Cost Efficiency & Long-Term Reliability:** Integrated design-to-delivery reduces project cost overruns and safeguards long-term operational efficiency.



Fabtech

Fabtech Technologies Limited (FTL), the flagship of the Fabtech Group, brings three decades of engineering excellence to deliver **start-to-finish** (turnkey solutions) for pharmaceutical, biotech, and healthcare facilities worldwide. With deep capabilities across **Process, Air & Water**, FTL integrates design, engineering, manufacturing, and validation to build GMP-compliant, energy-efficient, and contamination-controlled environments across **62 countries**.

Post-COVID, the MEA region's focus on pharmaceutical self-reliance has accelerated FTL's growth trajectory. Deriving **78% of revenue from MENA, GCC, and ECO Zone markets**, the Company expands through **FTS Cleanroom Systems LLC** and strategic joint ventures. With **20 secured projects worth ₹13,724.61 lakhs**, FTL continues to strengthen its position as a preferred partner for critical facility infrastructure.

Fabtech's asset-light, integrated model combines in-house manufacturing, advanced project execution, and minimal third-party dependency to ensure **speed, quality, and consistency**. By mastering the pillars of **Bio-Clean Air, Pure Water, and Precision Process Systems**, FTL empowers nations to build **resilient, sustainable, and future-ready healthcare manufacturing ecosystems**.



Key Facts & Figures



ISO-Certified
Operations



180+
Team Size Including
94+
Qualified Engineers



**Start-To-End
Turnkey**
Engineering Solutions
Provider



₹ 90,441.87 Lakhs
Of Order Book As Of July 31,
2025



135+ Projects
Delivered Globally



In-House Design &
Manufacturing Excellence



Presence in **62 Countries**
with
Global operations in
cleanrooms, HVAC, process and
automation



3 Decades of
Fabtech Group's
Legacy



Trusted By **Leading
Pharmaceutical & Biotech
Companies**

FY25 Financials & CAGR Growth (FY 2023-25)

₹ 33,594.21 Lakhs
Total Income

29.63 % CAGR

₹ 4,728.87 Lakhs
EBITDA


20.85 % CAGR

₹ 4,645.29 Lakhs
Net Profit

46.20 % CAGR

Turnkey Engineering Solutions: Driving Efficiency Across the Value Chain

How FABTECH Fits




Capex earmarked by pharmaceutical companies

Experienced turnkey engineering solution providers ensure successful completion/ upgrade of capex projects

Increased capabilities of pharmaceutical companies through optimal utilisation of capex

From Advisory to Post-Compliance Support: Start-to-End Services Covering the Entire Project Value Chain

— Fabtech Group: A Structured Legacy of Engineering Excellence



*Pursuant to TSA Share Purchase Agreement, Thermax Limited acquired 51% of equity share capital of our erstwhile associate company, TSA Process Equipments Private Limited ("TSA") and finalised the terms of acquisition of the remaining 49% in a staged manner spanning over a period of two years.

Order Book Details

Orders Received for the Period

(₹ in lakhs)

Particulars	FY25		FY24		FY23	
	Amount	%	Amount	%	Amount	%
Turnkey Projects	46,069.26	96.74%	35,409.84	87.76%	25,685.97	88.90%
Standalone Services	1,554.19	3.26%	4,940.39	12.24%	3,207.70	11.10%
Total	47,623.45	100.00%	40,350.23	100.00%	28,893.67	100.00%



Region Wise Break Up of Orders Received

(₹ in lakhs)

Particulars	FY25		FY24		FY23	
	Amount	%	Amount	%	Amount	%
MENA	18,510.03	38.87%	8,905.92	22.07%	9,254.83	32.03%
ECO Zone	12,786.37	26.85%	7,235.32	17.93%	16,269.30	56.31%
GCC	8,568.95	17.99%	22,662.29	56.16%	2,582.22	8.94%
SEA	7,719.18	16.21%	0.00	0.00%	551.33	1.91%
SADAC	25.27	0.05%	1,345.61	3.33%	69.78	0.24%
EUROPE	13.67	0.03%	201.09	0.50%	165.73	0.57%
AMERICA	0.00	0.00%	0.00	0.00%	0.48	0.00%
Total	47,623.45	100.00%	40,350.23	100.00%	28,893.67	100.00%

**₹ 90,441.87
Lakhs**

**Total Unexecuted
Order Book as on
31st July 2025**

Notable Projects Executed



State of Palestine

The Advanced Veterinary Co

Installation and commissioning of

- Cleanrooms and related equipment
- Heat ventilation and air conditioning systems
- Purified water generation system
- Water distribution systems and other ancillary equipment.



M/s. Qomel Company

The project executed for the customer included

- Supply, installation, and commissioning of equipment and utilities;
- Electro-mechanical works and water systems
- Installation, qualification, and validation of equipment.



Saudi Arabia



Bangladesh

Healthcare Pharmaceuticals Ltd

- Supply of Cleanroom Equipment
- Supply of isolator systems including Sampling isolators, Dispensing isolators, Compounding isolators.




M/s. Spectro Pharma

- Supply and commissioning of reach trucks for warehousing of disinfectants and general goods.
- Comprehensive employee training to ensure safe and optimal operations.



Saudi Arabia



Premier Food Industries

Installation and commissioning of

- HVAC systems
- Soft water distribution systems
- Setup of modular cleanroom partitions
- Installation of packing machines for OSD line
- Deployment of process equipment for ointment line



M/s. Laboratory & Allied Limited

The project executed for the customer included

- Construction of cleanrooms for QC Laboratory, Injectable, and OSD blocks.
- Installation of modular partitions, HVAC, and electrical systems.
- Epoxy flooring and utility piping works.
- Water treatment plant installation with related utilities.



Kenya



Kenya

Consolidated Result Highlights

Q2 FY26

H1 FY26



Total Income ↑ ₹ 12,427.61 Lakhs
103.39% YoY

₹ 19,322.80 Lakhs ↑ **Total Income**
109.91% YoY



EBITDA ↑ ₹ 3,363.53 Lakhs
383.76% YoY

₹ 2,839.99 Lakhs ↑ **EBITDA**
2,678.31% YoY



EBITDA Margin ↑ 27.06%
1,568.59 BPS

14.70% ↑ **EBITDA Margin**
1,358.72 BPS



Net Profit ↑ ₹ 2,810.61 Lakhs
449.12% YoY

₹ 2,198.02 Lakhs ↑ **Net Profit**
101.57% YoY



Net Profit Margin ↑ 22.62%
1,423.91 BPS

11.38% ↓ **Net Profit Margin**
-47.03 BPS



EPS ↑ ₹ 8.68

₹ 6.79 ↑ **EPS**



*Comparative figures for Q2 FY25 & H1 FY25

Restated Consolidated Profit & Loss Statement

Particulars	FY25	FY24	FY23
Revenues from Operations	32,666.85	22,613.63	19,379.75
Other Income	927.36	446.81	611.26
Total Income	33,594.21	23,060.44	19,991.01
Cost of Material	18,185.94	12,151.43	9,164.48
Employee Benefits Expenses	3,433.65	1,978.01	1,911.39
Finance Expenses	208.63	189.98	257.55
Depreciation & Amortisation Expenses	260.78	208.11	190.26
Other Expenses	7,278.92	5,094.02	6,041.23
Total Expenditure	29,367.92	19,621.56	17,564.91
Profit before Share of profits in associate entity, exceptional items and tax	4,226.29	3,438.88	2,426.10
Share of profits in associate entity	32.22	138.14	363.77
Profit before extraordinary items and tax	4,258.51	3,577.02	2,789.87
Extraordinary Items Prior Period Item	1,784.86	0.00	0.00
PBT	6,043.37	3,577.02	2,789.87
Tax	1,398.07	855.28	616.50
Net Profit	4,645.30	2,721.74	2,173.37
Other Comprehensive Income	(12.59)	0.73	(14.93)
Total Comprehensive Income	4,632.71	2,722.47	2,158.44

Restated Consolidated Balance Sheet

Equities & Liabilities	FY25	FY24	FY23
Equity Share Capital	3,239.22	294.48	278.59
Reserve & Surplus	14,072.17	12,893.74	8,617.69
Non-controlling Interest	(0.03)	(0.01)	0.00
Net Worth	17,311.36	13,188.21	8,896.28
Non-Current Liabilities			
Borrowings	53.44	27.68	86.47
Lease Liabilities	2,661.61	135.65	13.16
Provisions	82.02	82.64	155.37
Total Non Current Liabilities	2,797.07	245.97	255.00
Current Liabilities			
Borrowings	5,408.64	960.06	3,342.24
Lease Liabilities	258.82	148.04	103.03
Trade Payables	9,880.29	6,506.11	5,399.63
Other financial liabilities	28.31	108.08	19.78
Other Current Liabilities	6,295.07	5,585.12	3,293.47
Provisions	87.35	89.53	76.98
Current tax liabilities (net)	588.89	92.46	0.00
Total Current Liabilities	22,547.37	13,489.40	12,235.13
Total Equites & Liabilities	42,655.80	26,923.58	21,386.41

Assets	FY25	FY24	FY23
Non Current Assets			
Property, plant and equipment	5,648.99	555.82	355.37
Goodwill	3,699.81	1,610.42	0.00
Other Intangible assets	65.06	42.70	7.47
Investments	832.22	0.10	2,024.06
Loans	112.42	163.88	581.73
Other financial assets	650.60	260.51	149.11
Deferred tax asset	242.63	174.62	127.08
Total Non Current Assets	11,251.73	2,808.05	3,244.82
Current Assets			
Inventories	5,941.58	2,927.41	1,723.53
Investments	642.56	2,099.99	5.06
Trade Receivables	15,073.61	9,665.85	9,941.24
Cash & Cash Equivalents	905.56	2,899.17	1,052.94
Bank balances other than cash and cash equivalent	2,595.42	1,718.01	1,331.90
Loans	242.35	165.50	98.71
Other Financial Assets	3,549.58	2,574.62	2,006.88
Current Tax assets	4.63	4.18	32.30
Other current assets	1,885.43	911.12	1,949.03
Total Current Assets	30,840.72	22,965.85	18,141.59
Assets classified as held for sale	563.35	1,149.69	0.00
Total Assets	42,655.80	26,923.58	21,386.41

WE ARE COMMITTED TO
SAVING



Fabtech[®]
Technologies Limited
Life Engineering™

Fabtech Technologies Limited

Registered Office: 715, Janki Center, Off Veera
Desai Road, Andheri West, Mumbai 400 053,
Maharashtra, India

Phone: +91 226 159 2900

Corporate Office: 1st Floor, ABR Emerald, Plot
No D8, Street 16, MIDC Andheri East, Chakala
MIDC, Mumbai – 400 093, Maharashtra, India.

Phone: +91 226 554 0300

Email: cs@fabtechnologies.com

Website: www.fabtechnologies.com



AKMIL Strategic Advisors Private Limited

Address: Office No. 1011, 10th Floor, Opal
Square, Road No. 16, Wagle Estate,
Thane (w)-400 604, Maharashtra, India

Phone: +91 98209 41925

Email: info@akmiladvisors.com

Website: www.akmiladvisors.com

THANK YOU